• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cyclacel Pharmaceuti (NQ: CYCCP )

    6.820 -0.680 (-9.07%)
    Streaming Delayed Price Updated: 3:55 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Cyclacel Pharmaceuti

    < Previous 1 2 Next >
    Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
    - Interim data for fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities - 
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
    Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities 
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
    Delisting or suspension action stayed pending the issuance of a final decision 
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
    Lengthens Patent Exclusivity of Plogosertib until August 2040 
    From Cyclacel
    Via GlobeNewswire
    Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
    Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma 
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Reverse Stock Split
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
    From Cyclacel
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.